Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1

Interventions

pembrolizumab 382Carboplatin 279Specimen Handling 266Nivolumab 256Magnetic Resonance Spectroscopy 247Cyclophosphamide 242Cisplatin 217Paclitaxel 208Radiotherapy 196Biopsy 171Gemcitabine 158Dexamethasone 149durvalumab 148atezolizumab 128Rituximab 123Doxorubicin 117Bevacizumab 115Ipilimumab 114Lenalidomide 113Radiation 111Pemetrexed 104Docetaxel 104Etoposide 102venetoclax 98fludarabine 97Radiosurgery 94Capecitabine 94Fluorouracil 93Oxaliplatin 91Prednisone 90

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × LY-2157299 × 1 year × Clear all
NCT02688712 2026-04-13

ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

Providence Health & Services

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Rectal Neoplasms

NCT02452008 2025-12-19

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Active not recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡